NCT07230301
Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions
Not Yet Recruiting · Phase 2 · Sizhen Wang · registry updated 2025-11-17
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
1. Study: A Clinical Study of Intra-cavity Adebrelimab Combined with Best Supportive Care for Pancreatic Cancer Patients with Pleural or Peritoneal Effusion (Malignant Ascites) 2. Why is this study being done? This study is being done to find out if a new approach to treatment is safe and effective for controlling malignant fluid buildup (pleural or peritoneal effusion) in the abdomen or chest in patients with pancreatic cancer. The approach involves putting a drug called Adebrelimab directly into the fluid cavity, in combination with the best available supportive care chosen by your doctor. 3. What is Adebrelimab? Adebrelimab is a type of immunotherapy drug (a PD-L1 inhibitor) that helps the body's immune system fight cancer cells. It is already approved in China for treating some lung cancers. In this study, it is being given directly into the fluid buildup (intra-cavity) to see if it can work better there. 4. What will happen if I join the study? Screening: First, you will go through tests to see if you are eligible. Treatment: If eligible, the fluid will be drained. Then, Adebrelimab will be infused into the cavity on Day 1 and Day 8 of each 3-week cycle....
Inclusion
- Age ≥ 18 years.
- Histologically or cytologically confirmed pancreatic cancer.
- Presence of malignant pleural or peritoneal effusion (≥4 cm) confirmed by pathology or cytology, requiring clinical intervention.
- At least one measurable lesion according to RECIST v1.1.
- ECOG performance status 0-3.
- Estimated life expectancy ≥ 2 months.
Exclusion
- Asymptomatic effusion not requiring intervention.
- Contraindication to paracentesis or drainage.
- Contraindications to immunotherapy (e.g., chronic steroid use, prior immune-related pneumonitis, hepatitis, or colitis).
- Active autoimmune disease requiring systemic therapy.
- Active HCV, HIV, syphilis, or tuberculosis infection; uncontrolled severe infection within 4 weeks prior to first dose.
- History of allogeneic organ transplantation or autologous stem cell transplantation.